Tempest Therapeutics, Inc.
TPST
$0.91
-$0.08-7.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.43M | 5.43M | 3.54M | 3.03M | 895.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.25M | 5.54M | 4.08M | 3.60M | 4.77M |
| Operating Income | -5.25M | -5.54M | -4.08M | -3.60M | -4.77M |
| Income Before Tax | -5.24M | -27.70M | -4.02M | -3.51M | -7.87M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.24M | -27.70M | -4.02M | -3.51M | -7.87M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.24M | -27.70M | -4.02M | -3.51M | -7.87M |
| EBIT | -5.25M | -5.54M | -4.08M | -3.60M | -4.77M |
| EBITDA | -5.19M | -5.48M | -4.01M | -3.53M | -4.70M |
| EPS Basic | -0.34 | -2.53 | -0.82 | -0.79 | -2.07 |
| Normalized Basic EPS | -0.22 | -0.32 | -0.51 | -0.49 | -0.77 |
| EPS Diluted | -0.34 | -2.53 | -0.82 | -0.79 | -2.07 |
| Normalized Diluted EPS | -0.22 | -0.32 | -0.51 | -0.49 | -0.77 |
| Average Basic Shares Outstanding | 15.22M | 10.93M | 4.91M | 4.44M | 3.80M |
| Average Diluted Shares Outstanding | 15.22M | 10.93M | 4.91M | 4.44M | 3.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |